Shortcuts

open access

Vol 11, No 1 (2009)
Z piśmiennictwa europejskiego
Published online: 2009-03-19
Get Citation

Oxcarbazepine improves mood in patients with epilepsy

Marianna Mazza, Giacomo Della Marca, Marco Di Nicola, Giovanni Martinotti, Gino Pozzi, Luigi Janiri, Pietro Bria, Salvatore Mazza
Udar Mózgu. Problemy Interdyscyplinarne 2009;11(1):34-40.

open access

Vol 11, No 1 (2009)
Z piśmiennictwa europejskiego
Published online: 2009-03-19

Abstract

This study prospectively examined whether continued add-on treatment with oxcarbazepine (OXC) is associated with quantitative improvement in mood and anxiety symptoms in adult patients with partial epilepsy. Depressive symptoms and anxiety were assessed by clinical interview using the Hamilton Depression Rating Scale (HDRS), the Cornell Dysthymia Rating Scale (CDRS), the Beck Depression Inventory (BDI), and the Hamilton Anxiety Rating Scale (HARS). Forty controls (patients with epilepsy treated with antiepileptic drugs other than OXC) and 40 OXC-treated patients were enrolled and completed the study. In our study, a significant improvement in affect, as measured by the CDRS, was demonstrated during the course of OXC treatment for 3 months. HDRS and BDI scores also declined in the OXC-treated group, but these decreases did not reach statistical significance. In addition, 28 of 40 OXC-treated subjects who were dysthymic by CDRS criteria on study entry (score P20) demonstrated affective improvement consistent with a treatment-related antidepressant effect (score < 20). Although our results do not provide conclusive evidence supporting the specific use of OXC as an antidepressant, the significant decline in dysthymic symptoms in OXC-treated subjects compared with controls lends support to the hypothesis that OXC improves mood.

Abstract

This study prospectively examined whether continued add-on treatment with oxcarbazepine (OXC) is associated with quantitative improvement in mood and anxiety symptoms in adult patients with partial epilepsy. Depressive symptoms and anxiety were assessed by clinical interview using the Hamilton Depression Rating Scale (HDRS), the Cornell Dysthymia Rating Scale (CDRS), the Beck Depression Inventory (BDI), and the Hamilton Anxiety Rating Scale (HARS). Forty controls (patients with epilepsy treated with antiepileptic drugs other than OXC) and 40 OXC-treated patients were enrolled and completed the study. In our study, a significant improvement in affect, as measured by the CDRS, was demonstrated during the course of OXC treatment for 3 months. HDRS and BDI scores also declined in the OXC-treated group, but these decreases did not reach statistical significance. In addition, 28 of 40 OXC-treated subjects who were dysthymic by CDRS criteria on study entry (score P20) demonstrated affective improvement consistent with a treatment-related antidepressant effect (score < 20). Although our results do not provide conclusive evidence supporting the specific use of OXC as an antidepressant, the significant decline in dysthymic symptoms in OXC-treated subjects compared with controls lends support to the hypothesis that OXC improves mood.
Get Citation

Keywords

epilepsy; dystymia; depression; anxiety; oxcarbazepine

About this article
Title

Oxcarbazepine improves mood in patients with epilepsy

Journal

Interdisciplinary Problems of Stroke

Issue

Vol 11, No 1 (2009)

Pages

34-40

Published online

2009-03-19

Bibliographic record

Udar Mózgu. Problemy Interdyscyplinarne 2009;11(1):34-40.

Keywords

epilepsy
dystymia
depression
anxiety
oxcarbazepine

Authors

Marianna Mazza
Giacomo Della Marca
Marco Di Nicola
Giovanni Martinotti
Gino Pozzi
Luigi Janiri
Pietro Bria
Salvatore Mazza

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl